Fibrous dysplasia or McCune-Albright syndrome affects approximately 5 per 1,000,000 hospitalised patients in France, with ...
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa ...
ELLENSBURG, Wash. — Jack Keeling is a pretty big deal for a nine-year-old: he’s well-traveled, he has a dedicated Facebook page and he’s the youngest player ever drafted by the Central Washington ...
Atossa Therapeutics Inc, a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, announced that the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results